Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

S0030: Capecitabine in Treating Older Patients W/Metastatic or Recurrent Colorectal Cancer That Cannot Be Surgically Removed

Study:

Protocol For Assessment Of Capecitabine For Advanced Colorectal Cancer In Patients Aged 70 Years And Older (And In A Cohort Of Patients Younger Than 60 Years)

Rationale:

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Purpose:

Phase II trial to study the effectiveness of capecitabine in treating older patients who have metastatic or recurrent colorectal cancer that cannot be surgically removed.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Colorectal Cancer Drug: capecitabine Phase 2

Verified by Southwest Oncology Group January, 2013

Sponsored by: Southwest Oncology Group
Information provided by: Southwest Oncology Group
ClinicalTrials.gov identifier: NCT00049335

Study Type: Interventional

Study Design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195-9001
United States

Heinz-Josef Lenz, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site